Skip to main content

Table 2 CYP2C19, CYP2D6, CYP3A5, AND SULT1A1 genotype frequencies

From: Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

Genotype Predicted phenotypes (n) % of total Age (median) Genotypes (n) Genotype frequency
CYP2C191 *2/*2 (4) 4.4 63 *2/*2 (4) 0.03
  *1/*2 (15) 16.7 66 *1/*2 (15) 0.21
  *1/*1 (35) 38.9 62 *1/*1 (35) 0.35
  *1/*17 and *2/*17 (33) 36.7 62 *1/*17 (24) 0.27
      *2/*17 (9) 0.08
  *17/*17 (3) 3.3 65 *17/*17 (3) 0.05
CYP2D62 PM (6) 6.7 65 *4/*4 (4) 0.04
      *4/*5 (2) 0.01
  IM (32) 35.5 55 *1/*3 (1) 0.01
      *1/*4 (27) 0.29
      *1/*5 (3) 0.04
      *1/*6 (1) 0.01
  Wt/Wt (51) 56.7 60 *1/*1 (51) 0.48
  UM (1) 1.1 50 *1/*2 ×2 (1)  
CYP3A5 Vt/Vt (76) 84.4 60 *3/*3 (76) 0.85
  Wt/Vt (14) 15.6 73 *1/*3 (14) 0.50
  Wt/Wt (0)    *1/*1 (0)  
SULT1A1 Vt/Vt (14) 15.6 61 *2/*2 (14) 0.11
  Wt/Vt (32) 35.5 59 *1/*2 (32) 0.44
  Wt/Wt (44) 48.9 59 *1/*1 (44) 0.45
SULT1A1 copy numbers 1 (3) 3.3 59    
  2 (59) 65.6 60    
  3 (21) 23.3 67    
  4 (5) 5.6 72    
  5 (2) 2.2 69    
  1. 1*2/*2, subjects homozygous for the variant allele CYP2C19*2; *1/*2, subjects heterozygous for the variant allele CYP2C19*2; intermediate metabolizer, subjects homozygous for the wild type allele CYP2C19*1 and with CYP2C19*2/*17; *1/*17 subjects heterozygous for the CYP2C19*17 variant allele; *17/*17 Vt*17 subjects homozygous for the CYP2C19*17 variant allele
  2. 2PM, poor metabolizer CYP2D6; IM, intermediate metabolizer wild type/variant type CYP2D6; Wt/Wt, wild type/wild type CYP2D6; UM, ultra rapid metabolizer CYP2D6.